TRex aims to refine immune balance through therapies designed to promote tissue repair in patients suffering from autoimmune and inflammatory conditions. The company’s primary asset, TRB-061, functions as an investigational tumor necrosis factor receptor. Currently in development for atopic dermatitis, this candidate is expected to yield clinical results by mid-2027. A second program, TRB-071, targets inflammatory bowel disease and is slated to enter Phase 1 human trials in the first half of 2027.
Financial disclosures reveal the high-stakes nature of this development-stage work. For the six-month period ending June 30, the company reported a net loss of $11.6 million. While the filing outlines the intent to list, TRex has yet to disclose the specific pricing or the total volume of shares to be offered to investors.
Comments (0)
No comments yet. Be the first!